Germany Country Drug Report 2019
Germany
Country Drug Report 2019
About this report
Sections
What are the long-term aims of drug policy in Germany? How are these aims to be achieved? How is drug policy coordinated at national level?
Learn moreUnderstanding the costs of drug-related actions is an important aspect of policy evaluation.
Learn moreWhat substances and activities does Germany control under its drug laws? What are the penalties for offences? How are new psychoactive substances controlled?
Learn moreHow many people in Germany have ever used drugs? What drugs have they used? How many have used drugs recently? How many are using drugs in highly risky ways?
Learn moreWhat are the main infectious diseases linked to drug injecting in Germany?
Learn moreHow many drug-related medical emergencies occurred in Germany in the last year?
Learn moreHow many people died of drug overdoses or poisonings in Germany in the last year?
Learn moreWhat part does prevention play in Germany drug strategy. What are the main prevention approaches used in the country and who do they target?
How does Germany measure in terms of provision of needle and syringe programmes, peer naloxone programmes, supervised drug consumption rooms and heroin-assisted treatment.
Learn moreHow is the drug treatment system organised in Germany? How is it financed? How is the provision of treatment divided between inpatient and outpatient settings?
Learn moreWhat is done in Germany to ensure that the prevention and treatment interventions used are effective and provide a good return on public expenditure?
Learn moreIn which areas of study is drug-related research carried out in Germany? How is this research funded? Are any types of research emphasised in the national drug strategy?
What is known about drug supply and trafficking in Germany? How pure or strong are the drugs available? What do they cost? What are the main aims of supply reduction efforts?
Learn morePartners
About our partner in Germany
Following the establishment of the EMCDDA in 1993, the German Ministry for Health nominated the Federal Centre for Health Education (Bundeszentrale für gesundheitliche Aufklärung (BZgA), Cologne), the German Centre for Addiction Issues (Deutsche Hauptstelle für Suchtfragen e.V. (DHS), Hamm) and the IFT Institute for Therapy Research (IFT Institut für Therapiefoschung, Munich) to act jointly as the German national focal point (NFP) within the Reitox network of the EMCDDA. Together, the three institutions form the German Monitoring Centre for Drugs and Drug Addiction (DBDD) with the IFT as the institution responsible for the overall management of the NFP. Within the DBDD, the BZgA deals with prevention aspects, the DHS is mainly responsible for the working areas of addiction treatment and the IFT is responsible for epidemiology, drug policy, legal framework information, information on drug-related harms and harm reduction and the Early Warning System (EWS).
German national focal point
Deutsche Beobachtungsstelle für Drogen und Drogensucht (DBDD)
(German Monitoring Centre for Drugs and Drug Addiction)
c/o IFT Institut für Therapieforschung
Leopoldstr. 175
D-80804 München
Tel. +49 89 36 08 04 42
Fax. +49 89 36 08 04 49
Head of national focal point: Ms Esther Dammer
Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.